Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More
Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More
ABBOTT INDIA | NOVARTIS | ABBOTT INDIA/ NOVARTIS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 46.6 | 2,256.4 | 2.1% | View Chart |
P/BV | x | 15.2 | 30.0 | 50.9% | View Chart |
Dividend Yield | % | 0.5 | 1.5 | 30.6% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ABBOTT INDIA Mar-19 |
NOVARTIS Mar-19 |
ABBOTT INDIA/ NOVARTIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 8,834 | 980 | 901.4% | |
Low | Rs | 5,458 | 600 | 909.3% | |
Sales per share (Unadj.) | Rs | 1,731.1 | 198.7 | 871.1% | |
Earnings per share (Unadj.) | Rs | 211.9 | 21.0 | 1,010.7% | |
Cash flow per share (Unadj.) | Rs | 219.9 | 22.3 | 988.0% | |
Dividends per share (Unadj.) | Rs | 65.00 | 10.00 | 650.0% | |
Dividend yield (eoy) | % | 0.9 | 1.3 | 71.9% | |
Book value per share (Unadj.) | Rs | 945.2 | 307.5 | 307.4% | |
Shares outstanding (eoy) | m | 21.25 | 24.69 | 86.1% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.1 | 4.0 | 103.8% | |
Avg P/E ratio | x | 33.7 | 37.7 | 89.5% | |
P/CF ratio (eoy) | x | 32.5 | 35.5 | 91.5% | |
Price / Book Value ratio | x | 7.6 | 2.6 | 294.2% | |
Dividend payout | % | 30.7 | 47.7 | 64.3% | |
Avg Mkt Cap | Rs m | 151,848 | 19,508 | 778.4% | |
No. of employees | `000 | 3.5 | 0.6 | 599.8% | |
Total wages/salary | Rs m | 4,356 | 1,171 | 371.9% | |
Avg. sales/employee | Rs Th | 10,555.5 | 8,445.4 | 125.0% | |
Avg. wages/employee | Rs Th | 1,249.9 | 2,015.7 | 62.0% | |
Avg. net profit/employee | Rs Th | 1,292.2 | 891.0 | 145.0% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 36,786 | 4,907 | 749.7% | |
Other income | Rs m | 1,133 | 783 | 144.8% | |
Total revenues | Rs m | 37,919 | 5,689 | 666.5% | |
Gross profit | Rs m | 6,047 | 123 | 4,924.5% | |
Depreciation | Rs m | 169 | 32 | 532.1% | |
Interest | Rs m | 23 | 16 | 141.5% | |
Profit before tax | Rs m | 6,989 | 858 | 814.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,485 | 340 | 730.9% | |
Profit after tax | Rs m | 4,503 | 518 | 869.9% | |
Gross profit margin | % | 16.4 | 2.5 | 656.9% | |
Effective tax rate | % | 35.6 | 39.6 | 89.7% | |
Net profit margin | % | 12.2 | 10.6 | 116.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 27,610 | 8,055 | 342.8% | |
Current liabilities | Rs m | 8,569 | 1,850 | 463.2% | |
Net working cap to sales | % | 51.8 | 126.4 | 40.9% | |
Current ratio | x | 3.2 | 4.4 | 74.0% | |
Inventory Days | Days | 60 | 45 | 133.8% | |
Debtors Days | Days | 27 | 34 | 80.8% | |
Net fixed assets | Rs m | 1,057 | 150 | 705.5% | |
Share capital | Rs m | 213 | 123 | 172.2% | |
"Free" reserves | Rs m | 19,873 | 7,469 | 266.1% | |
Net worth | Rs m | 20,086 | 7,592 | 264.6% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 29,409 | 9,824 | 299.3% | |
Interest coverage | x | 311.6 | 54.9 | 567.1% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 1.3 | 0.5 | 250.4% | |
Return on assets | % | 15.4 | 5.4 | 283.3% | |
Return on equity | % | 22.4 | 6.8 | 328.8% | |
Return on capital | % | 34.9 | 11.5 | 303.3% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 369 | 58 | 640.6% | |
Fx outflow | Rs m | 4,918 | 1,326 | 370.8% | |
Net fx | Rs m | -4,549 | -1,269 | 358.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 4,991 | -1,943 | -256.9% | |
From Investments | Rs m | -2,570 | 2,742 | -93.7% | |
From Financial Activity | Rs m | -1,428 | -298 | 478.9% | |
Net Cashflow | Rs m | 993 | 501 | 198.1% |
Indian Promoters | % | 0.0 | 0.0 | - | |
Foreign collaborators | % | 75.0 | 75.0 | 100.0% | |
Indian inst/Mut Fund | % | 7.9 | 2.0 | 395.0% | |
FIIs | % | 0.1 | 1.6 | 6.3% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 17.1 | 21.5 | 79.5% | |
Shareholders | 18,270 | 41,647 | 43.9% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ABBOTT INDIA With: DR. REDDYS LAB STERLING BIOTECH NATCO PHARMA SUN PHARMA IPCA LABS
Compare ABBOTT INDIA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Share markets in India are presently trading marginally higher. The BSE Sensex is trading up by 140 points, up 0.3% at 49,538 levels.
For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
More Views on NewsThe smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Our ace stock picker is ready to capitalise on a big growth opportunity.
More